Every Mutation Matters

We realize that with limited samples to conduct research, scientists at academic institutions, biotechnology and pharmaceutical companies are not able to test and accelerate the work necessary to find a cure for every child with Duchenne. To remove this barrier, we have partnered with RUCDR Infinite Biologics and Dr. Tahseen Mozaffar from UC Irvine, to create the CureDuchenne Biobank which will collect minimally invasive blood and skin tissue samples that will be banked and made openly accessible for research.

CureDuchenne is committed to ensure that all patients, regardless of mutation, have their own cell lines available to test potential mutation-specific therapies.


To learn more and get the most up-to-date Biobank information, please fill out this form

or email Romina Foster-Bonds, Director of Programs at: biobank@cureduchenne.org

Director of Programs Romina


According to the National Organization for Rare Disorders, only 5% of rare diseases have a treatment approved by the Food and Drug Administration. This is due, in part, to the lack of high quality biospecimens for research.

At CureDuchenne, we are committed to removing any barriers to a cure.


We have launched the CureDuchenne Biobank; a collection of biological material and data from Duchenne patients and immediate relatives, stored in an organized system, that is accessible to all qualified Duchenne researchers.

CureDuchenne Logo
UCI Logo


The UCI Clinical team will be collecting minimally invasive biospecimens from patients with Duchenne and unaffected immediate relatives. We will be scheduling future collections alongside select CureDuchenne events across the country.

Skin Tissue Sample

Skin tissue samples

Blood Sample



Personalized Cell Lines

Patient cell lines specialized to each child can be used by any researcher to develop customized treatments. This is a critical step in de-risking the preclinical drug development stage.

Personalized Genomics

DNA and serum contribute to genetic and biomarker studies to understanding disease progression, prognosis and response to therapies.

Personalized Immunology

Peripheral blood mononuclear cells support research investigating how to harness the immune response to allow for more effective treatment.

Watch Biobank Webinar